The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis

Y Stabholz, M Paul - Clinical Microbiology and Infection, 2023 - Elsevier
Background Current practice guidelines favour fidaxomicin over vancomycin and exclude
metronidazole from the recommended standard regimen for Clostridioides difficile infection …

Hypervirulent R20291 Clostridioides difficile spores show disinfection resilience to sodium hypochlorite despite structural changes

D Malyshev, IA Jones, M McKracken, R Öberg… - BMC microbiology, 2023 - Springer
Background Clostridioides difficile is a spore forming bacterial species and the major
causative agent of nosocomial gastrointestinal infections. C. difficile spores are highly …

Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review

MJ Fernandez-Cotarelo, JY Jackson-Akers… - European Journal of …, 2023 - Springer
Purpose Clostridioides difficile infection (CDI) is the leading cause of antibiotic-related
diarrhea and healthcare-associated infections, affecting in particular elderly patients and …

[HTML][HTML] Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study

A Boven, E Vlieghe, L Engstrand, FL Andersson… - Clinical Microbiology …, 2023 - Elsevier
Objectives Clostridioides difficile infection (CDI) is a common healthcare-associated
infection and leading cause of gastroenteritis-related mortality worldwide. However, data on …

High Prevalence of Clostridioides difficile Ribotype 176 in the University Hospital in Kosice

K Curova, M Novotny, L Ambro, A Kamlarova… - Pathogens, 2023 - mdpi.com
Dysbiosis of the gut microbiota, caused by antibiotics, plays a key role in the establishment
of Clostridioides difficile CD). Toxin-producing strains are involved in the pathogenesis of …

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

CS Kraft, M Sims, M Silverman, TJ Louie… - Infectious Diseases and …, 2024 - Springer
Methods VOS or placebo [ECOSPOR III only](4 capsules once daily for 3 days). Integrated
analysis of treatment-emergent adverse events (TEAEs) collected through week 8; serious …

The ESCMID Study Group for Clostridioides difficile: History, Role, and Perspectives

JE Coia, EJ Kuijper, F Fitzpatrick - … Diseases and Public Health Volume 18, 2024 - Springer
Clostridioides difficile (C. difficile) is a major nosocomial pathogen but is also increasingly
recognised as an important diarrhoeal pathogen in the community, not always associated …

Erratum to: updates on Clostridium difficile in Europe

P Mastrantonio, M Rupnik - Updates on Clostridium difficile in Europe …, 2018 - Springer
MazE-MazFTA system, 100 metabolic and immunologic homeostasis, 98 mode of growth, 99
outermost exosporium layer, 100 photodynamic therapy, 110 quorum sensing, 98 spo0A …